Zinzani, P. L. Et Al. 2020. Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study. BLOOD , vol.136, no.Supplement 1 , 42-43.

Zinzani, P. L., Melnichenko, V., Bouabdallah, K., Walewski, J., Majlis, A., Fogliatto, L., ... Caballero, D.(2020). Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study. BLOOD , vol.136, no.Supplement 1, 42-43.

Zinzani, Pier Et Al. "Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study," BLOOD , vol.136, no.Supplement 1, 42-43, 2020

Zinzani, Pier L. Et Al. "Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study." BLOOD , vol.136, no.Supplement 1, pp.42-43, 2020

Zinzani, P. L. Et Al. (2020) . "Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study." BLOOD , vol.136, no.Supplement 1, pp.42-43.

@article{article, author={Pier Luigi Zinzani Et Al. }, title={Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study}, journal={BLOOD}, year=2020, pages={42-43} }